Pharmaceutical Analysis & Statistics, September 2014

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Publishers

  • All
    • Global Data

All regions

You might be interested in: therapeutics, drug, cancer, more »

1-30 of about 5 400 reports

Purchase Reports From Reputable Market Research Publishers

OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018

OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018

  • $ 7 995
  • Industry report
  • August 2014
  • by Global Data

OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018 Summary The competitive landscape in the B-cell NHL markets in the US, France, Italy, Germany, Spain and the ...

  • Industries : Pathology
  • Countries : United States
OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • August 2014
  • by Global Data

OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018 Summary The main drivers of growth in graft versus host disease over the 2013-2018 forecast period include the ...

  • Industries : Therapy
  • Countries : United States, World
OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020

OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020

  • $ 7 995
  • Industry report
  • July 2014
  • by Global Data

OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020 Summary Dengue is a febrile illness caused by the dengue virus (DENV), a single-stranded flavivirus most commonly transmitted ...

  • Industries : Drug and Medication
  • Countries : Singapore, Brazil, India, Mexico, Thailand, World
OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2018 - Event-Driven Update

OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2018 - Event-Driven Update

  • $ 7 995
  • Industry report
  • July 2014
  • by Global Data

OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2018 - Event-Driven Update Summary Cystic Fibrosis (CF) is an autosomal recessive disease characterized by the secretion of ...

  • Industries : Pathology
  • Countries : United States
OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

  • Industries : Pathology
PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through ...

  • Industries : Drug and Medication
  • Countries : Spain, France, Italy, Germany, United Kingdom, Europe, World
PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • July 2014
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded ...

  • Industries : Drug and Medication
  • Countries : Spain, Italy, France, Germany, United Kingdom, Europe, World
PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through ...

  • Industries : Drug and Medication
  • Countries : United States
PharmaPoint: Asthma - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Japan Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - Japan Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented ...

  • Industries : Drug and Medication
  • Countries : Japan
PharmaPoint: Asthma - Australia Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Australia Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - Australia Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented ...

  • Industries : Drug and Medication
  • Countries : Australia
PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023

PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • July 2014
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded ...

  • Industries : Drug and Medication
  • Countries : United States
PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • July 2014
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded ...

  • Industries : Drug and Medication
  • Countries : Japan
EpiCast Report: Asthma - Epidemiology Forecast to 2023

EpiCast Report: Asthma - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • September 2014
  • by Global Data

EpiCast Report: Asthma - Epidemiology Forecast to 2023 Summary Asthma is a chronic inflammatory lung disease that affects persons of all ages, but most commonly starts in childhood. It is a common long-term ...

  • Industries : Pathology
EpiCast Report: Breast Cancer (HER2-, HER2+) - Epidemiology Forecast to 2023

EpiCast Report: Breast Cancer (HER2-, HER2+) - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • September 2014
  • by Global Data

EpiCast Report: Breast Cancer (HER2-, HER2+) - Epidemiology Forecast to 2023 Summary Breast cancer is a malignant tumor that originates in the breast tissues. Most breast cancers are invasive tumors that ...

  • Industries : Pathology
  • Countries : Japan, World
EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023

EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • August 2014
  • by Global Data

EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023 Summary Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part ...

  • Industries : Pathology
  • Countries : Japan, China, World, United States, Spain, Italy, France, Germany
EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023

EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • July 2014
  • by Global Data

EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023 Summary Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences ...

  • Industries : Pathology
  • Countries : Germany, World, United States, Spain, United Kingdom, Italy, France, Japan
Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Brilinta (Acute Coronary Syndrome) - Forecast and ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Effient (Acute Coronary Syndrome) - Forecast and ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Crestor (Acute Coronary Syndrome) - Forecast and ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, United States, United Kingdom, Europe
Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Xarelto (Acute Coronary Syndrome) - Forecast and ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Angiomax (Acute Coronary Syndrome) - Forecast and ...

  • Industries : Pathology
  • Countries : World, United States, Spain, Italy, France, Germany, Japan, United Kingdom, Europe
Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Cangrelor (Acute Coronary Syndrome) - Forecast ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, United States, United Kingdom, Europe
Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Zontivity (Acute Coronary Syndrome) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Alirocumab (Acute Coronary Syndrome) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Evolocumab (Acute Coronary Syndrome) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Bococizumab (Acute Coronary Syndrome) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Anacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Anacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Anacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Anacetrapib (Acute Coronary Syndrome) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Evacetrapib (Acute Coronary Syndrome) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
North America Hernia Repair Market Outlook to 2020

North America Hernia Repair Market Outlook to 2020

  • $ 3 000
  • Industry report
  • July 2014
  • by Global Data

North America Hernia Repair Market Outlook to 2020 Summary GlobalData's new report, "North America Hernia Repair Market Outlook to 2020", provides key market data on the North America Hernia Repair market. ...

  • Industries : Pathology
  • Countries : North America, Mexico, Canada, United States
EU5 Hernia Repair Market Outlook to 2020

EU5 Hernia Repair Market Outlook to 2020

  • $ 3 000
  • Industry report
  • July 2014
  • by Global Data

EU5 Hernia Repair Market Outlook to 2020 Summary GlobalData's new report, "EU5 Hernia Repair Market Outlook to 2020", provides key market data on the EU5 Hernia Repair market. The report provides value, ...

  • Industries : Pathology
  • Countries : United Kingdom, Spain, Italy, France, Germany, Europe
About 57 000 reports

Download Unlimited Documents from Trusted Public Sources

Pathology Description in the US

  • National Gay Men's Hiv/aids Awareness Day - September 27, 2014
  • September 2014
    20 pages
  • Pathology  

    Hiv  

  • United States  

    North America  

View report >

Pathology Description

September 2014

Pathology Description

September 2014

Drug Supply In The Us

September 2014

93 Companies

Read our Company Profiles

GlaxoSmithKline P.L.C.

United States

Pfizer Inc.

United States

Johnson and Johnson

United States

GlaxoSmithKline PLC

United Kingdom

Novartis Inc.

Switzerland

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.